Genetic pathways in colorectal and other cancers

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 335-351

  Ilyas, M ^a   Straub, J ^a   Tomlinson, I P M ^b   Bodmer, W F ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Colorectal cancer; Genetic pathways; Genetics; Review

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; COLORECTAL CANCER; DISEASE COURSE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; METASTASIS; ONCOGENE K RAS; PRIORITY JOURNAL; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; MUTATION; WORLD HEALTH;

EID: 0033105411     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00431-6     Document Type: Review

References (209)

1. Foulds L. The natural history of cancer. J. Chronic Dis. 8:1958;2-37.
2. Farber E. Cancer development and its natural history. A cancer prevention perspective. Cancer. 62:(Suppl. 8):1988;1676-1679.
3. Bodmer W.F. The somatic evolution of cancer. The Harveian Oration of 1996. J. Royal Coll. Physicians London. 31:(1):1996;82-89.
4. Harwood J., Tachibana A., Meuth M. Multiple dispersed spontaneous mutations: a novel pathway of mutation in a malignant human cell line. Mol. & Cell. Biol. 11:(6):1991;3163-3170.
5. Wittenkeller J.L., Storer B., Bittner G., Schiller J.H. Comparison of spontaneous and induced mutation rates in an immortalized human bronchial epithelial cell line and its tumorigenic derivative. Oncology. 54:(4):1997;335-341.
6. Raff M.C. Social controls on cell survival and cell death. Nature. 356:(6368):1992;397-400.
7. Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizaki Y., Jacobson M.D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 262:(5134):1993;695-700.
8. Raff M.C. Cell death genes: Drosophila enters the field. Science. 264:(5159):1994;668-669.
9. Peifer M. Cancer, catenins, and cuticle pattern: a complex connection. Science. 262:1993;1667-1668.
10. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 81:(4):1995;495-504.
11. Cleveland J.L., Ihle J.N. Contenders in FasL/TNF death signaling. Cell. 81:(4):1995;479-482.
12. Bignami M., Rosa S., La-Rocca S.A., Falcone G., Tato F. Differential influence of adjacent normal cells on the proliferation of mammalian cells transformed by the viral oncogenes myc, ras and src. Oncogene. 2:(5):1988;509-514.
13. Del-Buono R., Pignatelli M., Bodmer W.F., Wright N.A. The role of the arginine-glycine-aspartic acid-directed cellular binding to type I collagen and rat mesenchymal cells in colorectal tumour differentiation. Differentiation. 46:(2):1991;97-103.
14. Tomlinson I.P., Bodmer W.F. Modelling the consequences of interactions between tumour cells. Br. J. Cancer. 75:(2):1997;157-160.
15. Tomlinson I.P. Game-theory models of interactions between tumour cells. Eur. J. Cancer. 33:(9):1997;1495-1500.
16. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:(2):1996;159-170.
17. Ilyas M., Tomlinson I.P. Genetic pathways in colorectal cancer. Histopathology. 28:(5):1996;389-399.
18. Strauss B.S. Hypermutability in carcinogenesis. Genetics. 148:(4):1998;1619-1626.
19. Weinberg R.A. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49:(14):1989;3713-3721.
20. Parada L.F., Land H., Weinberg R.A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 312:(5995):1984;649-651.
21. Lu X., Park S.H., Thompson T.C., Lane D.P. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell. 70:(1):1992;53-61.
22. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304:(5927):1983;596-602.
23. Balmain A., Nagase H. Cancer resistance genes in mice: models for the study of tumour modifiers. Trends in Genetics. 14:(4):1998;139-144.
24. Raha A., Tew K.D. Glutathione S-transferases. Cancer Treat and Res. 87:1996;83-122.
25. Fijneman R.J., de Vries S.S., Jansen R.C., Demant P. Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nature Genetics. 14:(4):1996;465-467.
26. van Wezel T., Stassen A.P., Moen C.J., Hart A.A., Van Der Valk M.A., Demant P. Gene interaction and single gene effects in colon tumour susceptibility in mice. Nature Genetics. 14:(4):1996;468-470.
27. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997, 386(6627), 761, 763.
28. Kinzler K.W., Vogelstein B. Landscaping the cancer terrain. Science. 280:(5366):1998;1036-1037.
29. Loeb L.A. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res. 54:(19):1994;5059-5063.
30. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51:(12):1991;3075-3079.
31. Tomlinson I.P., Novelli M.R., Bodmer W.F. The mutation rate and cancer. Proc. Natl. Acad. Sciences USA. 93:(25):1996;14800-14803.
32. Donehower L.A., Bradley A. The tumor suppressor p53. Biochim. Biophys. Acta. 1155:(2):1993;181-205.
33. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:(6381):1992;15-16.
34. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:(4):1992;523-526.
35. Carder P.J., Cripps K.J., Morris R., et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br. J. Cancer. 71:(2):1995;215-218.
36. Donehower L.A., Godley L.A., Aldaz C.M., et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes & Dev. 9:(7):1995;882-895.
37. Cahill D.P., Lengauer C., Yu J., et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 392:(6673):1998;300-303.
38. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature. 386:(6625):1997;623-627.
39. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:(13):1996;3087-3090.
40. Laken S.J., Petersen G.M., Gruber S.B., et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics. 17:(1):1997;79-83.
41. Gryfe R., Nicola N., Gallinger S., Redston M. Somatic instability of the APC I1307K allele in colorectal neoplasia. Cancer Res. 58:1998;4040-4043.
42. Myeroff L.L., Parsons R., Kim S.J., et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55:(23):1995;5545-5547.
43. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., Chang E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 348:(6303):1990;747-749.
44. Birch J.M. The Li-Fraumeni cancer family syndrome. J. Pathol. 161:(1):1990;1-2.
45. Tsongalis G.J., Linfert D.R., Johnson R.C., Ackroyd R., Berman M.M., Ricci Jr A. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch. Pathol. & Lab. Med. 112:(6):1998;548-550.
46. Anonymous. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997, 349(9064), 1505-1510.
47. HMSO. Cancer Statistics. Registrations. England and Wales. London, HMSO, 1989.
48. HMSO. Mortality Statistics. Cause. England and Wales. London, HMSO, 1992.
49. Levin B. Inflammatory bowel disease and cancer. Cancer 1992, 70, 1313-1316.
50. Sugita A., Sachar D.B., Bodian C., Ribeiro M.B., Aufses Jr J., Greenstein A.J. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut. 32:(2):1991;167-169.
51. Gillen C., Walmsley R., Prior P., Andrews H., Allan R. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 35:1994;1590-1592.
52. Haenszel W., Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J. Natl. Cancer Inst. 40:(1):1968;43-68.
53. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:(18):1994;4855-4878.
54. Yamashita N., Minamoto T., Ochiai A., Onda M., Esumi H. Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression? Cancer. 75:(Suppl. 6):1995;1527-1533.
55. Smith A.J., Stern H.S., Penner M., et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54:(21):1994;5527-5530.
56. Nucci M.R., Robinson C.R., Longo P., Campbell P., Hamilton S.R. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Human Pathol. 28:(12):1997;1396-1407.
57. Siu I.M., Pretlow T.G., Amini S.B., Pretlow T.P. Identification of dysplasia in human colonic aberrant crypt foci. Am. J. Pathol. 150:(5):1997;1805-1813.
58. Losi L., Roncucci L., di Gregorio C., de Leon M.P., Benhattar J. K-ras and p53 mutations in human colorectal aberrant crypt foci. J. Pathol. 178:(3):1996;259-263.
59. Ransohoff D.F., Lang C.A. Screening for colorectal cancer. New Engl. J. Med. 325:(1):1991;37-41.
60. Read T.E., Read J.D., Butterly L.F. Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. New Engl. J. Med. 336:(1):1997;8-12.
61. Atkin W.S., Morson B.C., Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. New Engl. J. Med. 326:(10):1992;658-662.
62. Phillips R, Spigelman A, Thomson J. Familial adenomatous polyposis and other polyposis syndromes. London, Edward Arnold, 1994.
63. Hofstad B., Vatn M.H., Andersen S.N., et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut. 39:(3):1996;449-456.
64. Muto T., Bussey H.J., Morson B.C. The evolution of cancer of the colon and rectum. Cancer. 36:(6):1975;2251-2270.
65. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:(5):1990;759-767.
66. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 328:(6131):1987;614-616.
67. Solomon E., Voss R., Hall V., et al. Chromosome 5 allele loss in human colorectal carcinomas. Nature. 328:(6131):1987;616-619.
68. Cottrell S., Bicknell D., Kaklamanis L., Bodmer W.F. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet. 340:(8820):1992;626-630.
69. Nakamura Y. The role of the adenomatous polyposis coli (APC) gene in human cancers. Adv. Cancer Res. 62:1993;65-87.
70. Powell S.M., Zilz N., Beazer-Barclay Y., et al. APC mutations occur early during colorectal tumorigenesis. Nature. 359:(6392):1992;235-237.
71. Groden J., Thliveris A., Samowitz W., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66:(3):1991;589-600.
72. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochimica et Biophysica Acta. 1332:(3):1997;F127-147.
73. Brensinger J.D., Laken S.J., Luce M.C., et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut. 43:(4):1998;548-552.
74. Spirio L., Olschwang S., Groden J., et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell. 75:(5):1993;951-957.
75. Rubinfeld B., Souza B., Albert I., et al. Association of the APC gene product with beta-catenin. Science. 262:(5140):1993;1731-1734.
76. Munemitsu S., Albert I., Souza B., Rubinfeld B., Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. U.S.A. 92:(7):1995;3046-3050.
77. Rubinfeld B., Albert I., Porfiri E., Munemitsu S., Polakis P. Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res. 57:(20):1997;4624-4630.
78. Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:(6):1998;1130-1134.
79. Ilyas M., Tomlinson I.P., Rowan A., Pignatelli M., Bodmer W.F. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:(19):1997;10330-10334.
80. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:(5307):1997;1787-1790.
81. Morin P.J., Vogelstein B., Kinzler K.W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA. 93:(15):1996;7950-7954.
82. He T., Sparks A., Rago C. Identification of c-MYC as a target of the APC pathway. Science. 281:(5382):1998;1509-1512.
83. Ilyas M., Tomlinson I.P.M. The interactions of APC, E-cadherin and β-catenin in tumour development and progression. J. Pathol. 182:1997;128-137.
84. Knudson Jr A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 68:(4):1971;820-823.
85. Levy D.B., Smith K.J., Beazer-Barclay Y., Hamilton S.R., Vogelstein B., Kinzler K.W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res. 54:(22):1994;5953-5958.
86. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene (published erratum appears in Science 1992, 22 May 256(5060), 1114). Science 1992, 256(5057), 668-670.
87. Shoemaker A., Moser A., Midgley C., Clipson L., Newton M., Dove W. A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice. Proc. Natl. Acad. USA. 95:(18):1998;10826-10831.
88. Cormier R.T., Hong K.H., Halberg R.B., et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nature Genetics. 17:(1):1997;88-91.
89. Gould K.A., Luongo C., Moser A.R., et al. Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics. 144:(4):1996;1777-1785.
90. Frayling I., Beck N., Ilyas M., et al. The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc. Natl. Acad. Sci. USA. 95:(18):1998;10722-10727.
91. Gama-Sosa M.A., Slagel V.A., Trewyn R.W., et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11:(19):1983;6883-6894.
92. Counts J., Goodman J. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell. 83:1995;13-15.
93. Laird P.W., Jackson-Grusby L., Fazeli A., et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 81:(2):1995;197-205.
94. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195:(3):1988;255-271.
95. Yang J.J., Kang J.S., Krauss R.S. Ras signals to the cell cycle machinery via multiple pathways to induce anchorage-independent growth. Mol. & Cell. Biol. 18:(5):1998;2586-2595.
96. Novak A., Hsu S.C., Leung-Hagesteijn C., et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc. Natl. Acad. Sci. USA. 95:(8):1998;4374-4379.
97. Wong Z.M., Choo B., Li M., Carey D.J., Cano-Gauci D.F., Buick R.N. Syndecan-1 is up-regulated in ras-transformed intestinal epithelial cells. Br. J. Cancer. 77:(6):1998;890-896.
98. Yan Z., Chen M., Perucho M., Friedman E. Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin beta1-chain maturation in colon epithelial cells. J. Biol. Chem. 272:(49):1997;30928-30936.
99. Whetsell L., Maw G., Nadon N., Ringer D.P., Schaeter F.V. Polymerase chain reaction micro-analysis of tumors from stained histological slides. Oncogene. 7:(11):1992;2355-2361.
100. Minamoto T., Yamashita N., Ochiai A., et al. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer. 75:(Suppl. 6):1995;1520-1526.
101. Chaubert P., Benhattar J., Saraga E., Costa J. K-ras mutations and p53 alterations in neoplastic lesions associated with longstanding ulcerative colitis. Am. J. Pathol. 144:(4):1994;767-775.
102. Jen J., Powell S.M., Papadopoulos N., et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54:(21):1994;5523-5526.
103. Keino-Masu K., Masu M., Hinck L., et al. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell. 87:(2):1996;175-185.
104. Riggins G.J., Thiagalingam S., Rozenblum E., et al. Mad-related genes in the human. Nature Genetics. 13:(3):1996;347-349.
105. Fazeli A., Dickinson S.L., Hermiston M.L., et al. Phenotype of mice lacking functional deleted in colorectal cancer (Dcc) gene. Nature. 386:(6627):1997;796-804.
106. Thiagalingam S., Lengauer C., Leach F.S., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics. 13:(3):1996;343-346.
107. Takagi Y., Kohmura H., Futamura M., et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology. 111:(5):1996;1369-1372.
108. Eppert K., Scherer S.W., Ozcelik H., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:(4):1996;543-552.
109. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell & Tissue Res. 292:(3):1998;435-445.
110. el-Deiry W.S., Harper J.W., O'Connor P.M., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:(5):1994;1169-1174.
111. Lynch H.T., Smyrk T.C., Lanspa S.J., et al. Phenotypic variation in colorectal adenoma/cancer expression in two families. Hereditary flat adenoma syndrome. Cancer. 66:(5):1990;909-915.
112. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science. 260:(5109):1993;812-816.
113. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 260:(5109):1993;816-891.
114. Jass J.R., Smyrk T.C., Stewart S.M., Lane M.R., Lanspa S.J., Lynch H.T. Pathology of Hereditary Non-Polyposis Colorectal Cancer. Anticancer Res. 14:1994;1631-1634.
115. Vasen H.F., Mecklin J.P., Khan P.M., Lynch H.T. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Diseases of the Colon & Rectum. 34:(5):1991;424-425.
116. Fishel R., Lescoe M.K., Rao M.R., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:(5):1993;1027-1038.
117. Leach F.S., Nicolaides N.C., Papadopoulos N., et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 75:(6):1993;1215-1225.
118. Bronner C.E., Baker S.M., Morrison P.T., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 368:(6468):1994;258-261.
119. Peltomaki P., Aaltonen L.A., Sistonen P., et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 260:(5109):1993;810-812.
120. Nicolaides N.C., Papadopoulos N., Liu B., et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 371:(6492):1994;75-80.
121. Yin J., Kong D., Wang S., et al. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Human Mutation. 10:(6):1997;474-478.
122. Modrich P. Mechanisms and biological effects of mismatch repair. Ann. Rev. Genet. 25:1991;229-253.
123. Herman J.G., Umar A., Polyak K., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA. 95:(12):1998;6870-6875.
124. Lengauer C., Kinzler K.W., Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl. Acad. Sci. USA. 94:(6):1997;2545-2550.
125. Leach F.S., Polyak K., Burrell M., et al. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res. 56:(2):1996;235-240.
126. Eshleman J.R., Lang E.Z., Bowerfind G.K., et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene. 10:(1):1995;33-37.
127. Parsons R., Li G.M., Longley M.J., et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 75:(6):1993;1227-1236.
128. Peltomaki P. Microsatellite instability and hereditary non-polyposis colon cancer. J. Pathol. 176:1995;329-330.
129. Lothe R.A., Peltomaki P., Meling G.I., et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 53:(24):1993;5849-5852.
130. Jass J.R., Do K.A., Simms L.A., et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 42:(5):1998;673-679.
131. Percesepe A., Kristo P., Aaltonen L., Deleon M., Delachapelle A., Peltomaki P. Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene. 17:(2):1998;157-163.
132. Hoang J.M., Cottu P.H., Thuille B., Salmon R.J., Thomas G., Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 57:(2):1997;300-330.
133. da Costa L.T., Liu B., el-Deiry W., et al. Polymerase delta variants in RER colorectal tumours. Nature Genetics. 9:(1):1995;10-11.
134. Kouri M., Laasonen A., Mecklin J.P., Jarvinen H., Franssila K., Pyrhonen S. Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry. Cancer. 65:(8):1990;1825-1829.
135. Jass J.R. Colorectal adenomas in surgical specimens from subjects with hereditary non-polyposis colorectal cancer. Histopathology. 27:1995;263-267.
136. Aaltonen L.A., Peltomaki P., Mecklin J.P., et al. Replication errors in benign and malignant tumours from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 54:(7):1994;1645-1648.
137. Huang J., Papadopoulos N., McKinley A.J., et al. APC mutations in colorectal tumors with mismatch repair deficiency. Proc. Natl. Acad. Sci. USA. 93:(17):1996;9049-9054.
138. Homfray T.F., Cottrell S.E., Ilyas M., et al. Defects in mismatch repair occur after APC mutations in the pathogenesis of sporadic colorectal tumours. Human Mutation. 11:(2):1998;114-120.
139. Eshleman J., Casey G., Kochera M., et al. Chromosome-number and structure both are markedly stable in rer colorectal cancers and are not destabilized by mutation of p53. Oncogene. 17:(6):1998;719-725.
140. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:(5215):1995;1336-1338.
141. Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours (published erratum appears in Nat Genet 1996, 14(4), 488). Nat Genet 1996 14(3), 255-257.
142. Rampino N., Yamamoto H., Ionov Y., et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 275:(5302):1997;967-969.
143. Souza R.F., Yin J., Smolinski K.N., et al. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res. 57:(12):1997;2350-2353.
144. Gyde S., Prior P., Allan R., et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 29:1988;206-217.
145. Connell W.R., Talbot I.C., Harpaz N., et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 35:(10):1994;1419-1423.
146. Morson B, Dawson I, Day D, Jass J, Price A, Williams G. In Morson B, Dawson I, eds. Morson and Dawson's gastrointestinal pathology. Third edn. Oxford, Blackwell Scientific Publications, 1990.
147. Riddell R., Goldman H., Ransohoff D., et al. Dysplasia in inflammatory bowel disease: standardised classification with provisional clinical applications. Hum. Pathol. 14:(11):1983;931-968.
148. Ilyas M., Tomlinson I.P., Hanby A.M., Yao T., Bodmer W.F., Talbot I.C. Bcl-2 expression in colorectal tumors: evidence of different pathways in sporadic and ulcerative-colitis-associated carcinomas. Am. J. Pathol. 149:(5):1996;1719-1726.
149. Richman P.I., Tilly R., Jass J.R., Bodmer W.F. Colonic pericryptal fibroblast sheath cells: characterisation of cell type with a new monoclonal antibody. J. Clin. Pathol. 40:(6):1987;593-600.
150. Yao T., Tsuneyoshi M. Significance of pericryptal fibroblasts in colorectal epithelial tumours: a special reference to the histologic features and growth patterns. Hum. Pathol. 24:(5):1993;525-533.
151. Brentnall T.A., Crispin D.A., Rabinovitch P.S., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 107:(2):1994;369-378.
152. Burmer G.C., Crispin D.A., Kolli V.R., et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun. 3:(6):1991;167-172.
153. Yin J., Harpaz N., Tong Y., et al. p53 Point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 104:(6):1993;1636-1639.
154. Rubin C.E., Haggitt R.C., Burmer G.C., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 103:(5):1992;1611-1620.
155. Porschen R., Robin U., Schumacher A., et al. DNA aneuploidy in Crohn's disease and ulcerative colitis: results of a comparative flow cytometric study. Gut. 33:(5):1992;663-667.
156. Meling G.I., Clausen O.P., Bergan A., Schjolberg A., Rognum T.O. Flow cytometric DNA ploidy pattern in dysplastic mucosa, and in primary and metastatic carcinomas in patients with longstanding ulcerative colitis. Br. J. Cancer. 64:(2):1991;339-344.
157. Fozard J.B., Quirke P., Dixon M.F., Giles G.R., Bird C.C. DNA aneuploidy in ulcerative colitis. Gut. 27:(12):1986;1414-1418.
158. Redston M., Papadopoulos N., Caldas C., Kinzler K., Kern S. Common occurrence of APC and K-ras mutation in the spectrum of colitis-associated neoplasias. Gastroenterology. 108:1995;383-392.
159. Tarmin L., . Yin J., Harpaz N., et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 55:(10):1995;2035-2038.
160. Bell S.M., Kelly S.A., Hoyle J.A., et al. C-ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. Br. J. Cancer. 64:(1):1991;174-178.
161. Meltzer S.J., Mane S.M., Wood P.K., et al. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res. 50:(12):1990;3627-3630.
162. Burmer G.C., Levine D.S., Kulander B.G., Haggitt R.C., Rubin C.E., Rabinovitch P.S. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology. 99:(2):1990;416-420.
163. Brentnall T.A., Crispin D.A., Bronner M.P., et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 56:(6):1996;1237-1240.
164. Heinen C.D., Noffsinger A.E., Belli J., et al. Regenerative lesions in ulcerative colitis are characterized by microsatellite mutation. Genes, Chromosomes & Cancer. 19:(3):1997;170-175.
165. Tomlinson I.P., Hampson R., Karran P., Bodmer W.F. DNA mismatch repair in lymphoblastoid cells from hereditary non-polyposis colorectal cancer (HNPCC) patients is normal under conditions of rapid cell division and increased mutational load. Mut. Res. 383:(2):1997;177-182.
166. Tada S., Iida M., Yao T., Matsumoto T., Tsuneyoshi M., Fujishima M. Stereomicroscopic examination of surface morphology in colorectal epithelial tumors. Hum. Pathol. 24:(11):1993;1243-1252.
167. Kuramoto S., Oohara T. Minute cancers arising de-novo in the human large intestine. Cancer. 61:(4):1988;829-834.
168. Yokota T., Sugihara K., Yokoyama T., et al. Small depressed cancer of the large bowel: report of three cases. Am. J. Gastroenterol. 90:(1):1995;134-136.
169. Yao T., Tada S., Tsuneyoshi M. Colorectal counterpart of gastric depressed adenoma. A comparison with flat and polypoid adenomas with special reference to the development of pericryptal fibroblasts. Am. J. Surg. Pathol. 18:(6):1994;559-568.
170. Fujimori T., Satonaka K., Yamamura-Idei Y., Nagasako K., Maeda S. Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int. J. Cancer. 57:(1):1994;51-55.
171. Yamagata S., Muto T., Uchida Y., et al. Lower incidence of K-ras codon 12 mutation in flat colorectal adenomas than in polypoid adenomas. Jpn. J. Cancer Res. 85:(2):1994;147-151.
172. Yukawa M., Fujimori T., Maeda S., Tabuchi M., Nagasako K. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut. 35:(9):1994;1258-1261.
173. Tada S., Yao T., Iida M., Koga H., Hizawa K., Fujishima M. A clinicopathologic study of small flat colorectal carcinoma. Cancer. 74:(9):1994;2430-2435.
174. Kuramoto S., Oohara T. How do colorectal cancers develop? Cancer. 75:(Suppl. 6):1995;1534-1538.
175. Jeghers H., McCusick V., Katz K. Generalised intestinal polyposis and melanin spots of the oral mucosa, lips and digits: a syndrome of diagnostic significance. New Engl. J. Med. 241:1949;1031-1036.
176. McColl I., Bussey H., Veale A., Morson B. Juvenile polyposis coli. Proc. Roy. Soc. Med. 57:1964;896-897.
177. Whitelaw S.C., Murday V.A., Tomlinson I.P., et al. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology. 112:(2):1997;327-334.
178. Gentry Jr W.C., Eskritt N.R., Gorlin R.J. Multiple hamartoma syndrome (Cowden disease). Arch. Dermatol. 109:(4):1974;521-525.
179. Howe J.R., Roth S., Ringold J.C., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280:(5366):1998;1086-1088.
180. Hemminki A., Markie D., Tomlinson I., et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 391:(6663):1998;184-187.
181. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:(1):1997;64-67.
182. Wu T.T., Rezai B., Rashid A., et al. Genetic alterations and epithelial dysplasia in juvenile polyposis syndrome and sporadic juvenile polyps. Am. Journal Pathol. 150:(3):1997;939-947.
183. Longacre T.A., Fenoglio-Preiser C.M. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am. J. Surg. Pathol. 14:(6):1990;524-537.
184. Jeevaratnam P., Cottier D.S., Browett P.J., Van De Water N.S., Pokos V., Jass J.R. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J. Pathol. 179:(1):1996;20-25.
185. Ajioka Y., Watanabe H., Jass J.R., Yokota Y., Kobayashi M., Nishikura K. Infrequent K-ras codon 12 mutation in serrated adenomas of human colorectum. Gut. 42:(5):1998;680-684.
186. Hiyama T., Yokozaki H., Shimamoto F., et al. Frequent p53 gene mutations in serrated adenomas of the colorectum. J. Pathol. 186:(2):1998;131-139.
187. Uchida H., Ando H., Maruyama K., et al. Genetic alterations of mixed hyperplastic adenomatous polyps in the colon and rectum. Jpn. J. Cancer Res. 89:(3):1998;299-306.
188. Bravard A., Luccioni C., Muleris M., Lefrancois D.B.D. Relationships between umpk and pgd activities and deletions of chromosome 1p in colorectal cancers. Cancer Genet. Cytogenet. 56:(1):1991;45-56.
189. Bardi G., Johansson B., Pandis N., et al. Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathological features. Cancer. 71:(2):1993;306-314.
190. Atkin N.B., Baker M.C. Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet. Cytogenet. 67:(2):1993;123-125.
191. Zenklusen J., Thompson J., Kleinszanto A., Conti C. Frequent loss of heterozygosity in human primary squamous-cell and colon carcinomas at 7q32.1 - evidence for a broad range tumor-suppressor gene. Cancer Res. 55:(6):1995;1347-1350.
192. Young J., Leggett B., Ward M., et al. Frequent loss of heterozygosity on chromosome-14 occurs in advanced colorectal carcinomas. Oncogene. 8:(3):1993;671-675.
193. Leggett B., Young J., Buttenshaw R., et al. Colorectal carcinomas show frequent allelic loss on the long arm of chromosome-17 with evidence for a specific target region. Br. J. Cancer. 71:(5):1995;1070-1073.
194. Purdie C., Piris J., Bird C., Wyllie A. 17q allele loss is associated with lymph-node metastasis in locally aggressive human colorectal-cancer. J. Pathol. 175:(3):1995;297-302.
195. Iino H., Fukayama M., Maeda Y., et al. Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer. 73:(5):1994;1324-1331.
196. Yana I., Kurahashi H., Nakamori S., et al. Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers. Int. J. Cancer. 60:(2):1995;174-177.
197. Frayling I.M., Bodmer W.F., Tomlinson I.P. Allele loss in colorectal cancer at the Cowden disease/juvenile polyposis locus on 10q. Cancer Genetics & Cytogenetics. 97:(1):1997;64-69.
198. Bronner M.P., Culin C., Reed J.C., Furth E.E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumour progression model. Am. J. Pathol. 146:(1):1995;20-26.
199. Hague A., Moorghen M., Hicks D., Chapman M., Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene. 9:(11):1994;3367-3370.
200. Sier C.F., Kubben F.J., Ganesh S., et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer. 74:(3):1996;413-417.
201. Sier C.F., Vloedgraven H.J., Griffioen G., et al. Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. Br. J. Cancer. 71:(2):1995;393-396.
202. Martinez J.A., Prevot S., Nordlinger B., et al. Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut. 37:(5):1995;712-720.
203. Furuta K., Zahurak M., Yang X.L., et al. Relationship between CD44 expression and cell proliferation in epithelium and stroma of colorectal neoplasms. Am. J. Pathol. 149:(4):1996;1147-1155.
204. Furuta K., Zahurak M., Goodman S.N., Hamilton S.R., August J.T. CD44 expression in the stromal matrix of colorectal cancer: association with prognosis. Clin. Cancer Res. 4:(1):1998;21-29.
205. Ilyas M., Tomlinson I.P., Hanby A., Talbot I.C., Bodmer W.F. Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers. Gut. 40:(5):1997;654-659.
206. Takaku K., Oshima M., Miyoshi H., Matsui M., Seldin M.F., Taketo M.M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 92:(5):1998;645-656.
207. Chawengsaksophak K., James R., Hammond V.E., Kontgen F., Beck F. Homeosis and intestinal tumours in Cdx2 mutant mice. Nature. 386:(6620):1997;84-87.
208. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:(5):1996;803-809.
209. Zhu Y., Richardson J., Parada L., Graff J. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714.